Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates

Peter Peduzzi, John Concato, Alvan R. Feinstein et al. · Journal of Clinical Epidemiology · 1995 · 2.1K citations · Full text

Public Health, Biostatistics, Clinical Epidemiology +12

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood · 2006 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · Journal of Clinical Oncology · 2012 · 990 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

Nita Agar, Emma Wedgeworth, Siobhan Crichton et al. · Journal of Clinical Oncology · 2010 · 845 citations

Medicine, Dermatology, Oncology +17